MCID: ART021
MIFTS: 54

Arteriosclerosis

Categories: Cardiovascular diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Arteriosclerosis

MalaCards integrated aliases for Arteriosclerosis:

Name: Arteriosclerosis 11 53 5 43 14 16 71 75
Arteriosclerotic Vascular Disease 11

Classifications:



External Ids:

Disease Ontology 11 DOID:2349
MeSH 43 D001161
NCIt 49 C34398
SNOMED-CT 68 195251000
ICD10 31 I70
UMLS 71 C0003850

Summaries for Arteriosclerosis

Disease Ontology: 11 An artery disease that is characterized by a thickening and hardening of arterial walls in the arteries.

MalaCards based summary: Arteriosclerosis, also known as arteriosclerotic vascular disease, is related to arteriosclerosis obliterans and aortic atherosclerosis, and has symptoms including angina pectoris An important gene associated with Arteriosclerosis is HS3ST1 (Heparan Sulfate-Glucosamine 3-Sulfotransferase 1), and among its related pathways/superpathways are Metabolism and Extracellular matrix organization. The drugs Nicotinamide and Progesterone have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and smooth muscle, and related phenotypes are Increased free cholesterol and homeostasis/metabolism

Wikipedia: 75 Arteriosclerosis is the thickening, hardening, and loss of elasticity of the walls of arteries. This... more...

Related Diseases for Arteriosclerosis

Diseases in the Arteriosclerosis family:

Arteriosclerosis, Severe Juvenile

Diseases related to Arteriosclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 578)
# Related Disease Score Top Affiliating Genes
1 arteriosclerosis obliterans 32.9 VCAM1 MIR21 MIR126 ICAM1 ADIPOQ
2 aortic atherosclerosis 32.5 VCAM1 ICAM1 CCL2 APOE APOB APOA1
3 atherosclerosis susceptibility 32.5 VCAM1 SERPINE1 PPARG PON1 MGP ICAM1
4 arterial calcification of infancy 32.4 SPP1 MGP ADIPOQ
5 cerebral atherosclerosis 32.4 MIR126 APOE APOB APOA1
6 coronary heart disease 1 32.4 SERPINE1 PON1 HMGCR APOE APOB APOA1
7 hyperlipoproteinemia, type iii 32.3 HMGCR APOE APOB APOA1
8 pseudoxanthoma elasticum 32.1 SPP1 SERPINE1 MGP ELN
9 hypercholesterolemia, familial, 1 31.8 HMGCR APOE APOB APOA1
10 angina pectoris 31.4 ICAM1 EDN1 APOA1
11 familial hyperlipidemia 31.4 SERPINE1 PPARG PON1 HMGCR APOE APOB
12 buerger disease 31.4 VCAM1 ICAM1 EDN1
13 peripheral vascular disease 31.4 VCAM1 SERPINE1 MIR126 ICAM1 HMGCR EDN1
14 lipoprotein quantitative trait locus 31.4 VCAM1 SERPINE1 PPARG PON1 MIR21 MIR126
15 hypertriglyceridemia 1 31.3 SERPINE1 APOE APOB APOA1
16 hypolipoproteinemia 31.3 APOE APOB APOA1
17 familial hypercholesterolemia 31.2 SERPINE1 PON1 HMGCR APOE APOB APOA1
18 vascular disease 31.1 VCAM1 SERPINE1 PPARG PON1 MIR21 MIR126
19 abdominal obesity-metabolic syndrome 1 31.1 SERPINE1 PPARG APOB ADIPOQ
20 hyperhomocysteinemia 31.0 VCAM1 SERPINE1 PON1 CCL2 APOE
21 hypothyroidism 31.0 SERPINE1 PON1 APOE APOB APOA1 ADIPOQ
22 stroke, ischemic 31.0 SERPINE1 PON1 MIR21 MIR126 HMGCR APOE
23 lipid metabolism disorder 31.0 VCAM1 SERPINE1 PPARG PON1 MIR21 MIR126
24 cerebrovascular disease 31.0 PON1 MIR21 MIR126 HMGCR APOE APOB
25 takayasu arteritis 31.0 VCAM1 ICAM1 EDN1 CCL2
26 carotid stenosis 30.9 VCAM1 SPP1 ICAM1 APOE ADIPOQ
27 coronary stenosis 30.9 SERPINE1 PON1 MIR21 ICAM1 APOE APOB
28 myocardial infarction 30.9 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR21
29 hyperlipoproteinemia, type i 30.9 APOE APOB APOA1
30 hypertension, essential 30.9 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR21
31 chronic kidney disease 30.8 SPP1 PON1 MIR21 MIR126 MGP HMGCR
32 aortic aneurysm 30.8 SPP1 SERPINE1 MIR21 MIR126 ELN CCL2
33 microvascular complications of diabetes 1 30.8 VCAM1 ICAM1 EDN1 CCL2
34 hyperinsulinism 30.8 SERPINE1 PPARG EDN1 APOB ADIPOQ
35 hyperglycemia 30.8 VCAM1 SERPINE1 PPARG MIR126 APOB ADIPOQ
36 non-alcoholic fatty liver disease 30.7 SERPINE1 PPARG MIR21 MIR126 HMGCR APOB
37 pulmonary hypertension 30.7 SPP1 SERPINE1 MIR21 HMOX1 ELN EDN1
38 systemic lupus erythematosus 30.7 VCAM1 SPP1 PPARG PON1 MIR21 ICAM1
39 hypoalphalipoproteinemia, primary, 1 30.6 APOE APOB APOA1
40 glucose intolerance 30.6 VCAM1 PPARG CCL2 APOA1 ADIPOQ
41 proteasome-associated autoinflammatory syndrome 1 30.6 VCAM1 PPARG ICAM1 CCL2 ADIPOQ
42 apnea, obstructive sleep 30.6 ICAM1 EDN1 APOE ADIPOQ
43 cardiovascular system disease 30.6 VCAM1 SERPINE1 PPARG PON1 MIR21 MIR126
44 kidney disease 30.6 VCAM1 SPP1 SERPINE1 PPARG PON1 MIR21
45 hyperuricemia 30.6 PPARG APOE APOB
46 uremia 30.6 SPP1 PON1 MGP
47 intermediate coronary syndrome 30.6 VCAM1 MIR21 MIR126 EDN1 APOB APOA1
48 prediabetes syndrome 30.6 SERPINE1 PPARG MIR21 MIR126 APOB APOA1
49 peripheral artery disease 30.6 VCAM1 MIR21 MIR126 ICAM1 CCL2 APOE
50 type 2 diabetes mellitus 30.5 VCAM1 SERPINE1 PPARG PON1 MIR21 MIR126

Graphical network of the top 20 diseases related to Arteriosclerosis:



Diseases related to Arteriosclerosis

Symptoms & Phenotypes for Arteriosclerosis

UMLS symptoms related to Arteriosclerosis:


angina pectoris

GenomeRNAi Phenotypes related to Arteriosclerosis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased free cholesterol GR00340-A-2 8.92 APOA1 APOB APOE HMGCR

MGI Mouse Phenotypes related to Arteriosclerosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.35 ADIPOQ APOA1 APOB APOE CCL2 DAB2IP
2 muscle MP:0005369 10.21 ADIPOQ APOB APOE CCL2 EDN1 ELN
3 growth/size/body region MP:0005378 10.17 ADIPOQ APOB APOE CCL2 EDN1 HMGCR
4 cellular MP:0005384 10.13 ADIPOQ APOA1 APOB APOE CCL2 DAB2IP
5 liver/biliary system MP:0005370 10.1 ADIPOQ APOA1 APOB APOE CCL2 HMGCR
6 renal/urinary system MP:0005367 10.06 ADIPOQ APOE EDN1 HMOX1 MGP PPARG
7 cardiovascular system MP:0005385 10.06 ADIPOQ APOA1 APOB APOE CCL2 EDN1
8 respiratory system MP:0005388 9.56 ADIPOQ APOE ELN HMOX1 MGP MIR126
9 mortality/aging MP:0010768 9.53 ADIPOQ APOB APOE CCL2 EDN1 ELN

Drugs & Therapeutics for Arteriosclerosis

Drugs for Arteriosclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 244)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
2
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
3
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
4
Polyestradiol phosphate Approved Phase 4 28014-46-2
5
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
6
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
7
Remifentanil Approved Phase 4 132875-61-7 60815
8
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
9
Atenolol Approved Phase 4 29122-68-7 2249
10
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
11
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
12
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
13
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
14
Pravastatin Approved Phase 4 81093-37-0 54687
15
Insulin aspart Approved Phase 4 116094-23-6 16132418
16
Insulin detemir Approved Phase 4 169148-63-4 16137271
17
Zinc cation Approved, Experimental, Investigational Phase 4 7440-66-6, 23713-49-7 32051
18
Alendronic acid Approved Phase 4 121268-17-5, 66376-36-1 2088
19
Acetaminophen Approved Phase 4 103-90-2 1983
20
Dipyridamole Approved Phase 4 58-32-2 3108
21
Ezetimibe Approved Phase 4 163222-33-1 150311
22
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
23
Calcium acetate Approved, Investigational Phase 4 62-54-4
24
Sevelamer Approved Phase 4 52757-95-6 3085017
25
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
26
Probucol Approved, Investigational Phase 4 23288-49-5 4912
27
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
28
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
29
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
30
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
31
Iron Approved Phase 4 7439-89-6 29936
32
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
33
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
34
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
35
Mycophenolic acid Approved, Investigational Phase 4 24280-93-1 446541
36
Tacrolimus Approved, Investigational Phase 4 104987-11-3 6473866 445643
37
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198
38
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
39
Evolocumab Approved Phase 4 1256937-27-5
40
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
41
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
42
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
43
Beraprost Investigational Phase 4 88430-50-6 2352 5282428
44 Folate Phase 4
45 Vitamin B9 Phase 4
46 Vitamin B3 Phase 4
47 Nicotinic Acids Phase 4
48 Vitamin B Complex Phase 4
49 Neurotransmitter Agents Phase 4
50 Progestins Phase 4

Interventional clinical trials:

(show top 50) (show all 343)
# Name Status NCT ID Phase Drugs
1 Evaluation of Antiplatelet Therapy in Lower Limb Endovascular Treatment Unknown status NCT00912756 Phase 4 cilostazol
2 The Low HDL On Six Weeks Statin Therapy (LOW) Study Unknown status NCT00238004 Phase 4 Nicotinic acid
3 Effects of Estrogen Replacement on Atherosclerosis Progression in Recently Menopausal Women Unknown status NCT00154180 Phase 4 Conjugated equine estrogens 0.45 mg/day;Transdermal estradiol, 50 mcg/day;Micronized progesterone, 200 mg/day x 12 d/month;CEE , progesterone, estradiol patch or placebo for each;CEE, progesterone, transdermal patch or the placebo
4 Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI) Unknown status NCT01777503 Phase 4 prasugrel;Clopidogrel
5 A Randomised, Placebo Controlled, Double Blind, Cross-over, Single Center Clinical Study to Investigate the Effect of Heart Rate Reduction With Ivabradine on Vascular Elastic Properties and Endothelial Function in Patients With Stable Coronary Heart Disease Unknown status NCT01768585 Phase 4 Ivabradine;Placebo
6 Intensive Statin Treatment in Acute Ischemic Stroke Patients With INtracranial Atherosclerosis - High-Resolution Magnetic Resonance Imaging Study (STAMINA-MRI Study) Unknown status NCT02458755 Phase 4 High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
7 Effects of Melatonin on Progression of Coronary Artery Calcification Unknown status NCT03966235 Phase 4 Melatonin 3 mg;Placebo
8 A Randomized, Control,Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker Completed NCT00823849 Phase 4 Cilostazol;Probucol;Cilostazol+Probucol
9 Comparison of Intravenous Anesthetics and Volatile Anesthetics on Postoperative Cognitive Dysfunction of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities. Completed NCT02107170 Phase 4 Sevoflurane;Propofol;Remifentanil
10 Reducing Total Cardiovascular Risk in an Urban Community Completed NCT00241904 Phase 4 Antiplatelet Agents;Beta Blocker;ACE Inhibitors
11 A Prospective, Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Atorvastatin Versus Pravastatin on the Progression and Quantification of Coronary Atherosclerotic Lesions as Measured by Intravascular Ultrasound (REVERSAL) Completed NCT00380939 Phase 4 Atorvastatin;Pravastatin
12 The Effect of Metformin Versus Placebo, Including Three Insulin-Analogue Regimens With Variating Postprandial Glucose Regulation, on CIMT in T2DM Patients - A Randomized, Multicenter Trial Completed NCT00657943 Phase 4 metformin;insulin detemir;insulin aspart + insulin aspart protamin;Insulin aspart
13 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT00496938 Phase 4
14 ACTFAST (2): Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration: A Multicenter, Twelve-Week Treatment, Single-Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 mg, 20 mg, 40 mg, And 80 mg. Completed NCT00442325 Phase 4 Atorvastatin (Lipitor)
15 Randomised Controlled Trial of the Effect of Alendronate on Vascular Calcification and Arterial Stiffness in Chronic Kidney Disease: A Pilot Study Completed NCT00395382 Phase 4 Alendronate;Placebo
16 The Ontario Multidetector Computed Tomography (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
17 Prospective, Randomized, Comparative Study to Evaluate the Effect of Iodixanol 320 Compared to Iomeprol 350 on Contrast Medium Induced Nephropathy in Patients With Impaired Renal Function Undergoing PCI Completed NCT00390585 Phase 4 Iodixanol 320;Iomeprol 350
18 Paracetamol and Endothelial Function in Patients With Stable Coronary Artery Disease Completed NCT00534651 Phase 4 Paracetamol
19 ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg Completed NCT00442845 Phase 4 Atorvastatin (Lipitor)
20 Prospective, Randomized Trial of Drug-eluting Stents vs. Bare Metal Stents for the Reduction of Restenosis in Bypass Grafts. Completed NCT00611910 Phase 4
21 ESPRIT: European/Australasian Stroke Prevention in Reversible Ischaemia Trial Completed NCT00161070 Phase 4 anticoagulation;aspirin and dipyridamole;aspirin alone
22 Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Completed NCT00110448 Phase 4 Aspirin;No aspirin
23 Capturing Outcomes of Clinical Activities Performed by a Rounding Pharmacist Practising in a Team Environment (COLLABORATE) Completed NCT00351676 Phase 4 Optimizing therapeutic treatments
24 A Single Center, Randomized, Parallel Groups, Placebo-Controlled Study Comparing The Efficacy, Safety, And Tolerability Of The Daily Co-administration Of Ezetimibe 10 Mg Or Ezetimibe Placebo To Ongoing Treatment With Atorvastatin 10 Mg In Subjects With Primary Hypercholesterolemia And Multiple Coronary Heart Disease Risk Factors in Indonesian Population. Completed NCT00319449 Phase 4 Ezetimibe;Placebo;Atorvastatin 10 mg
25 Effects of Celecoxib on Restenosis After Percutaneous Coronary Intervention and Evolution of Atherosclerosis (COREA) Trial Completed NCT00292721 Phase 4 Celecoxib
26 CARE-2 (Calcium Acetate (PhosLo®)/Sevelamer(Renagel®) Evaluation Study 2) Completed NCT00211939 Phase 4 calcium acetate;sevelamer;atorvastatin
27 A Prospective, Randomized, Multicenter Comparison of the Drug-Eluting Stent Systems YUKON Choice and TAXUS Liberté in Patients With Diabetes Mellitus Completed NCT00368953 Phase 4
28 Pilot Study: Inflammation and Coronary Artery Disease. Role of AT1 Receptor Antagonism Completed NCT00274144 Phase 4 telmisartan 40 mg;placebo 40 mg
29 A Multicenter, Randomized Double-Blind Study Comparing The Pleiotropic Effects Of Atorvastatin 10 Mg And 80 Mg Over A 26-Week Period In Subjects With Coronary Atherosclerosis Completed NCT00163202 Phase 4 Atorvastatin
30 A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation. Completed NCT00129038 Phase 4 modified-release dipyridamole/aspirin;aspirin
31 Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial Completed NCT02510547 Phase 4
32 Preprocedural Asprin Reload for Native Coronary Disease Treated by Angioplasty: Reperfusion Indexes Evaluation and Improvement of Clinical Outcome -PANTAREI Study Completed NCT01374698 Phase 4 Aspirin
33 Randomized Controlled Trial of Paclitaxel Drug-coated Balloons vs. Nitinol Stent for Femoropopliteal Obstructions - The PAVENST Trial Completed NCT02212470 Phase 4
34 Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery Completed NCT01334866 Phase 4
35 A Clinical Evaluation of the XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Women With de Novo Coronary Artery Lesions Completed NCT01182428 Phase 4
36 A Randomized, Control, Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker---atherosclerosis Cerebral Infarction Patient as Study Subject Completed NCT00823875 Phase 4 Cilostazol group;Probucol group;Cilostazol + Probucol group;control group
37 Multicenter Double-blind Placebo-controlled Randomized Parallel-group Clinical Study of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis Completed NCT03485495 Phase 4 Divaza;Placebo
38 Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD): A Prospective, Multicenter, Randomized, Controlled Trial Recruiting NCT04624854 Phase 4 Clopidogrel and Aspirin dual-antiplatelet therapy;Aspirin monotherapy
39 The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques: a Prospective, Random, Single-center Study Based on High Resolution Magnetic Resonance Imaging Recruiting NCT03753555 Phase 4 Atorvastatin Calcium;Probucol;PCSK9 inhibitor
40 Predicting Stroke Risk in Intracranial Atherosclerotic Disease With Novel High Resolution, Functional and Molecular MRI Techniques Recruiting NCT05515874 Phase 4 Feraheme
41 High-Resolution Assessment of Extracranial Plaques in a Multiple Centers Evolocumab Randomized Study Not yet recruiting NCT05585151 Phase 4 Evolocumab 140 MG/ML;Intensive statin treatment
42 Combination of Beraprost Sodium Tablets (Dorner) and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients Terminated NCT02786979 Phase 4 Beraprost;Aspirin
43 Randomised Comparison of Two Different Immunosuppressive Regimens on Progression of Arteriosclerosis in Renal Transplant Patients. Terminated NCT01276834 Phase 4 everolimus
44 Randomized-controlled Trial of a Combined vs. Conventional Percutaneous Intervention for Near-Infrared Spectroscopy Defined High-Risk Native Coronary Artery Lesions Terminated NCT02601664 Phase 4
45 EARly Prevention of aTHeroma Progression Terminated NCT02105623 Phase 4 Rosuvastatin
46 A Double Blind, 2:1 Randomised Monocentre Study to Investigate the Efficacy and Safety of Telmisartan (80 mg qd) Concerning the Amelioration of Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients (SAFE-CRP: Structural Alterations and Function of Endothelium in Cardiovascular Risk Patients) Terminated NCT00274105 Phase 4 telmisartan;Placebo
47 Reducing Intracranial atheroSclErosis With Repatha Terminated NCT04573777 Phase 4 Repatha
48 Multicenter Clinical Trial for Development of Guidelines of Adequate Blood Pressure Lowering in the Subacute Ischemic Stroke Patients Due to Intracranial Atherosclerosis Terminated NCT01104311 Phase 4
49 Study of Urinary Kallikrein to Enhance Collateral Circulation in Symptomatic Intracranial Atherosclerosis: a Study Based on Whole-brain CTP Withdrawn NCT04325932 Phase 4 Urinary Kallikrein
50 The Effectiveness of Ranolazine in Reducing Cardiac Ischaemia Induced by Chronic Total Occlusions of Coronary Arteries Withdrawn NCT02423265 Phase 4 Ranolazine;Placebo

Search NIH Clinical Center for Arteriosclerosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Epoprostenol
Epoprostenol Sodium
Isoxsuprine
Isoxsuprine Hydrochloride

Cochrane evidence based reviews: arteriosclerosis

Genetic Tests for Arteriosclerosis

Anatomical Context for Arteriosclerosis

Organs/tissues related to Arteriosclerosis:

MalaCards : Heart, Endothelial, Smooth Muscle, Bone Marrow, Kidney, Bone, Brain

Publications for Arteriosclerosis

Articles related to Arteriosclerosis:

(show top 50) (show all 12338)
# Title Authors PMID Year
1
HS3ST1 genotype regulates antithrombin's inflammomodulatory tone and associates with atherosclerosis. 5
28126521 2017
2
Assessing the function of genetic variants in candidate gene association studies. 5
15266341 2004
3
Decrease in glomerular filtration rate by plasma low-density lipoprotein cholesterol in subjects with normal kidney function assessed by urinalysis and plasma creatinine. 53 62
20097344 2010
4
Aldosterone antisecretagogue and antihypertensive actions of adrenomedullin in patients with primary aldosteronism. 53 62
20150911 2010
5
Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. 53 62
20078196 2010
6
Wild-type apo A-I and apo A-I(Milano) gene transfer reduce native and transplant arteriosclerosis to a similar extent. 53 62
19066833 2009
7
Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells. 53 62
19132220 2008
8
Relationships of adiponectin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome. 53 62
18464944 2008
9
Analysis of plasma adipocytokines related to clinical and laboratory data in the maintenance hemodialysis patients. 53 62
18670142 2008
10
Influence of serum high-molecular-weight and total adiponectin on arteriosclerosis in IgA nephropathy patients. 53 62
18332637 2008
11
[Endothelin-1 production and its involvement in cardiovascular diseases]. 53 62
17827914 2007
12
[Pioglitazone protects against elastocalcinosis and improves aortic wall elasticity]. 53 62
17489075 2007
13
General anesthesia and methylenetetrahydrofolate reductase deficiency. 53 62
18008117 2007
14
[Effects of recombinant adenovirus encoding human apM1 gene on proliferation and nitric oxide synthase activity in human umbilical vein endothelial cells]. 53 62
17274908 2006
15
Endothelial-mediated regulation of cerebral microcirculation. 53 62
17244945 2006
16
Upregulation of proteinase-activated receptors and hypercontractile responses precede development of arterial lesions after balloon injury. 53 62
16844909 2006
17
Pathophysiologic and therapeutic implications of adrenomedullin in cardiovascular disorders. 53 62
16616959 2006
18
TGF-beta1 generates a specific multicomponent extracellular matrix in human coronary SMC. 53 62
16796604 2006
19
Protective genes in the vessel wall: Modulators of graft survival and function. 53 62
16829794 2006
20
Signaling and functions of angiopoietin-1 in vascular protection. 53 62
16645151 2006
21
Recent advances in the relationship between obesity, inflammation, and insulin resistance. 53 62
16613757 2006
22
[Effects of active components extracted from Qixue Bingzhi Recipe on proliferation of vascular smooth muscle cells and expressions of platelet-derived growth factor and its receptor genes]. 53 62
16409966 2006
23
Adrenomedullin: a protective factor for blood vessels. 53 62
16141406 2005
24
Tempol attenuates the development of hypertensive renal injury in Dahl salt-sensitive rats. 53 62
15882555 2005
25
Matrix Gla protein and osteopontin genetic associations with coronary artery calcification and bone density: the CARDIA study. 53 62
15744522 2005
26
Endothelial nitric oxide synthase gene transfer restores endothelium-dependent relaxations and attenuates lesion formation in carotid arteries in apolipoprotein E-deficient mice. 53 62
15578196 2005
27
Increased plasma lipid-poor apolipoprotein A-I in patients with coronary artery disease. 53 62
15550473 2005
28
[Endothelin-1 and arteriosclerosis]. 53 62
15506470 2004
29
CD14 C(-260)T gene polymorphism, circulating soluble CD14 levels and arteriosclerosis. 53 62
15257175 2004
30
Eukaryotic expression vector of heme oxygenase-1 and its expression in endothelial cell. 53 62
15313669 2004
31
[The antioxidant function of high density lipoproteins: a new paradigm in atherosclerosis]. 53 62
15225502 2004
32
Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and type 1 diabetic patients. 53 62
15181084 2004
33
Inhibition of accelerated graft arteriosclerosis by gene transfer of soluble fibroblast growth factor receptor-1 in rat aortic transplants. 53 62
15072997 2004
34
Tumor necrosis factor alpha activates the human plasminogen activator inhibitor-1 gene through a distal nuclear factor kappaB site. 53 62
14963043 2004
35
A microsatellite polymorphism in the heme oxygenase-1 gene promoter is associated with increased bilirubin and HDL levels but not with coronary artery disease. 53 62
14691581 2004
36
Attenuation of aortic graft arteriosclerosis by systemic administration of Allotrap peptide RDP58. 53 62
12942166 2003
37
[Neurological aspects in antiphospholipid syndrome]. 53 62
15152454 2003
38
Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. 53 62
14583180 2003
39
Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury. 53 62
14581407 2003
40
[Regulatory effect of yishou tiaozhi tablet on lipids in patients with primary hyperlipidemia]. 53 62
12764909 2003
41
Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. 53 62
12628953 2003
42
Mouse endothelial CD40 expression does not play a role during the development of transplant arteriosclerosis. 53 62
12791519 2003
43
The concentration of lipids, lipoproteins and apolipoproteins in cord blood serum of newborns in the course of intrauterine period. 53 62
15323161 2003
44
Antiinflammatory and antiarteriosclerotic effects of pioglitazone. 53 62
12411463 2002
45
Upregulation of PAI-1 is mediated through TGF-beta/Smad pathway in transplant arteriopathy. 53 62
12231371 2002
46
Hepatocyte growth factor and 24-hour ambulatory blood pressure monitoring. 53 62
12452315 2002
47
Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. 53 62
12616975 2002
48
Gene therapy targeting monocyte chemoattractant protein-1 for vascular disease. 53 62
12560586 2002
49
A survey of the dietary nutritional composition of centenarians. 53 62
11677774 2001
50
[Effect of lower androgen levels on arteriosclerosis]. 53 62
11769606 2001

Variations for Arteriosclerosis

ClinVar genetic disease variations for Arteriosclerosis:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HS3ST1 NM_005114.4(HS3ST1):c.-108-6848A>G SNV Risk Factor
441163 rs16881446 GRCh37: 4:11408585-11408585
GRCh38: 4:11406961-11406961

Expression for Arteriosclerosis

Search GEO for disease gene expression data for Arteriosclerosis.

Pathways for Arteriosclerosis

Pathways related to Arteriosclerosis according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.71 PPARG PON1 HS3ST1 HMOX1 HMGCR APOE
2
Show member pathways
12.57 VCAM1 SPP1 SERPINE1 ICAM1 ELN
3
Show member pathways
12.41 PPARG HMGCR APOA1 ADIPOQ
4
Show member pathways
12.22 SPP1 APOE APOB APOA1
5
Show member pathways
12.04 SERPINE1 HMOX1 APOB APOA1
6
Show member pathways
12 VCAM1 SPP1 SERPINE1 ICAM1
7 11.74 SERPINE1 ICAM1 CCL2
8
Show member pathways
11.73 SPP1 PPARG ADIPOQ
9
Show member pathways
11.71 APOA1 APOB APOE
10 11.7 CCL2 HMOX1 ICAM1 VCAM1
11
Show member pathways
11.68 PPARG APOA1 ADIPOQ
12 11.61 ICAM1 ELN CCL2
13 11.6 VCAM1 SPP1 PPARG ADIPOQ
14 11.53 SERPINE1 HMOX1 EDN1
15
Show member pathways
11.44 HMGCR APOE APOB APOA1
16 11.4 CCL2 ICAM1 VCAM1
17 11.3 VCAM1 CCL2 ADIPOQ
18 11.15 MGP HMOX1 CCL2
19 11.07 VCAM1 ICAM1 HMOX1
20 11.05 VCAM1 MIR21 MIR126 ICAM1
21 10.82 SPP1 HMOX1 ELN EDN1 CCL2
22 10.54 VCAM1 ICAM1 CCL2

GO Terms for Arteriosclerosis

Cellular components related to Arteriosclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.48 SPP1 SERPINE1 PON1 MGP ELN EDN1
2 collagen-containing extracellular matrix GO:0062023 10 SERPINE1 MGP ICAM1 ELN APOE APOA1
3 extracellular vesicle GO:1903561 9.88 MIR21 MIR126 APOE APOA1
4 very-low-density lipoprotein particle GO:0034361 9.85 APOE APOB APOA1
5 endocytic vesicle lumen GO:0071682 9.8 APOE APOB APOA1
6 spherical high-density lipoprotein particle GO:0034366 9.78 PON1 APOA1
7 extracellular space GO:0005615 9.74 ADIPOQ APOA1 APOB APOE CCL2 EDN1
8 intermediate-density lipoprotein particle GO:0034363 9.73 APOB APOE
9 chylomicron GO:0042627 9.73 APOA1 APOB APOE
10 high-density lipoprotein particle GO:0034364 9.56 PON1 APOE APOB APOA1

Biological processes related to Arteriosclerosis according to GeneCards Suite gene sharing:

(show all 36)
# Name GO ID Score Top Affiliating Genes
1 lipid metabolic process GO:0006629 10.18 PPARG PON1 HMGCR APOE APOB APOA1
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.17 APOE CCL2 ICAM1 MIR126 MIR21
3 cellular response to hypoxia GO:0071456 10.16 PPARG MIR126 HMOX1 EDN1
4 response to hypoxia GO:0001666 10.15 VCAM1 HMOX1 EDN1 ADIPOQ
5 negative regulation of cell migration GO:0030336 10.14 SERPINE1 MIR21 MIR126 ADIPOQ
6 positive regulation of angiogenesis GO:0045766 10.13 HMOX1 MIR126 MIR21 SERPINE1
7 intermembrane lipid transfer GO:0120009 10.12 APOE APOB APOA1
8 response to nicotine GO:0035094 10.08 VCAM1 HMOX1 EDN1
9 negative regulation of vascular associated smooth muscle cell proliferation GO:1904706 10.08 ADIPOQ HMOX1 PPARG
10 cellular response to tumor necrosis factor GO:0071356 10.07 APOB CCL2 DAB2IP EDN1 VCAM1
11 negative regulation of smooth muscle cell proliferation GO:0048662 10.05 PPARG HMOX1 APOE
12 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 10.03 SERPINE1 ICAM1 HMOX1
13 cholesterol efflux GO:0033344 10.02 APOE APOB APOA1
14 negative regulation of endothelial cell apoptotic process GO:2000352 9.98 SERPINE1 MIR126 ICAM1
15 negative regulation of inflammatory response GO:0050728 9.97 PPARG MIR126 APOE APOA1 ADIPOQ
16 positive regulation of CoA-transferase activity GO:1905920 9.96 APOE APOA1
17 regulation of Cdc42 protein signal transduction GO:0032489 9.96 APOE APOA1
18 high-density lipoprotein particle clearance GO:0034384 9.94 APOE APOA1
19 membrane to membrane docking GO:0022614 9.93 ICAM1 VCAM1
20 lipoprotein catabolic process GO:0042159 9.93 APOB APOE
21 positive regulation of fatty acid metabolic process GO:0045923 9.92 ADIPOQ PPARG
22 positive regulation of cholesterol metabolic process GO:0090205 9.92 APOA1 APOE
23 negative regulation of endothelial cell migration GO:0010596 9.91 MIR21 DAB2IP APOE
24 low-density lipoprotein particle clearance GO:0034383 9.91 HMOX1 APOB ADIPOQ
25 cholesterol metabolic process GO:0008203 9.91 PON1 HMGCR APOE APOB APOA1
26 positive regulation of phospholipid efflux GO:1902995 9.89 APOE APOA1
27 negative regulation of blood coagulation GO:0030195 9.88 SERPINE1 EDN1 APOE
28 negative regulation of vascular endothelial cell proliferation GO:1905563 9.85 PPARG MIR126 CCL2
29 steroid metabolic process GO:0008202 9.84 HMGCR APOE APOB APOA1
30 response to organic substance GO:0010033 9.83 SPP1 PPARG APOB
31 lipoprotein metabolic process GO:0042157 9.8 APOA1 APOB APOE
32 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.78 MIR21 MIR126 HMOX1
33 cellular response to prostaglandin stimulus GO:0071379 9.7 PPARG APOB
34 negative regulation of MAP kinase activity GO:0043407 9.65 PPARG HMGCR DAB2IP APOE ADIPOQ
35 lipoprotein biosynthetic process GO:0042158 9.63 APOA1 APOB APOE
36 positive regulation of cholesterol efflux GO:0010875 9.32 PPARG PON1 APOE APOA1 ADIPOQ

Molecular functions related to Arteriosclerosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.9 SERPINE1 EDN1 CCL2 APOE APOA1 ADIPOQ
2 phospholipid binding GO:0005543 9.86 PON1 APOE APOB APOA1
3 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.62 APOE APOA1
4 lipid transporter activity GO:0005319 9.26 APOE APOB APOA1
5 cholesterol transfer activity GO:0120020 9.1 APOE APOB APOA1

Sources for Arteriosclerosis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....